Although Orkambi is priced lower than its predecessor Kalydeco, Vertex Pharmaceuticals Inc. may have made a very smart move by somewhat sidestepping the current controversy over expensive specialty drug costs while banking on volume to still grow its revenues.
Why Pricing Orkambi Below Kalydeco Is A Savvy Strategy For Vertex
Orkambi is the first combo drug to be priced lower than solo therapy with one of its components, but it stands to increase Vertex’s patient base exponentially.